Polysomnography Device - Market Insights, Competitive Landscape, and Market Forecast - 2032

Polysomnography (PSG) Devices Market Summary

• The global polysomnography devices market is expected to increase from USD 265.88 million in 2024 to USD 392.05 million by 2032, reflecting strong and sustained growth.
• The global polysomnography devices market is growing at a CAGR of 5.02% during the forecast period from 2025 to 2032.
• The market of polysomnography devices is being primarily driven by the rising prevalence of sleep disorders, increasing awareness about sleep health, increasing demand for home sleep testing, increasing technological advancements in PSG devices, and an increase in product development activities among the key market players.
• The leading companies operating in the polysomnography devices market include Koninklijke Philips N.V., Compumedics Limited, Natus Medical Incorporated, Nox Medical, ResMed, SOMNOmedics GmbH, Cadwell Industries, Inc., CleveMed, Nihon Kohden Corporation, Grass Technologies, Medcare, Vyaire Medical, Neurovirtual, Cidelec, BMC Medical, Natus Medical Incorporated, Bitmed, Neurosoft, Recorders & Medicare Systems, EB Neuro, and others.
• North America is expected to dominate the overall polysomnography devices market due to the high prevalence of sleep disorders, particularly obstructive sleep apnea, coupled with a large undiagnosed patient population. The region benefits from advanced healthcare infrastructure, strong adoption of innovative PSG technologies, and favorable reimbursement policies that support both in-lab and home-based sleep studies. Additionally, rising awareness about the health risks linked to poor sleep and strong presence of leading manufacturers such as Philips Respironics, Natus Medical, and ResMed further strengthen North America's market leadership.
• In the product segment of the polysomnography devices market, the stationary category is estimated to account for the largest market share in 2024.

Factors Contributing to the Growth of the Polysomnography Devices Market

• Rising prevalence of sleep disorders leading to a surge in polysomnography devices: The rising prevalence of sleep disorders such as obstructive sleep apnea, insomnia, and narcolepsy is driving a significant surge in demand for polysomnography (PSG) devices. With millions of patients remaining undiagnosed worldwide, there is growing reliance on PSG systems for accurate detection and management of these conditions. This increasing disease burden, coupled with greater awareness of the health risks associated with poor sleep, is fueling the adoption of both stationary and portable PSG devices across hospitals, clinics, and home healthcare settings.
• Increasing demand for home sleep testing is escalating the market of polysomnography devices: The increasing demand for home sleep testing is boosting the polysomnography (PSG) devices market, as patients and healthcare providers seek more convenient, cost-effective, and comfortable alternatives to traditional in-lab studies. Portable PSG devices allow for accurate diagnosis of sleep apnea and related disorders in a home setting, reducing hospital burden while expanding access to sleep diagnostics. This shift toward home-based monitoring is accelerating market growth and driving wider adoption of portable PSG systems.
• Increasing technological advancements in PSG devices: Increasing technological advancements in polysomnography (PSG) devices are boosting the market by making sleep studies more accurate, patient-friendly, and efficient. Innovations such as wireless sensors, cloud-based data sharing, AI-driven scoring, and portable multi-channel systems enhance diagnostic precision while improving patient comfort. These advancements are encouraging broader adoption of PSG devices across hospitals, sleep labs, and home healthcare settings, thereby accelerating overall market growth.

Polysomnography Devices Market Report Segmentation

This polysomnography devices market report offers a comprehensive overview of the global Polysomnography Devices market, highlighting key trends, growth drivers, challenges, and opportunities. It covers detailed market segmentation by Product Type (Stationary and Portable), Channel Configuration (>10 Channels, >16 Channels, >32 Channels, and >36 Channels), End-User (Hospitals, Clinics, and Homecare Settings), and geography. The report provides valuable insights into the competitive landscape, regulatory environment, and market dynamics across major markets, including North America, Europe, and Asia-Pacific. Featuring in-depth profiles of leading industry players and recent product innovations, this report equips businesses with essential data to identify market potential, develop strategic plans, and capitalize on emerging opportunities in the rapidly growing Polysomnography Devices market.

Polysomnography (PSG) devices are medical instruments used to monitor and record various physiological functions during sleep. They are primarily used to diagnose sleep disorders such as sleep apnea, narcolepsy, restless leg syndrome, insomnia, and other conditions affecting sleep quality.

The polysomnography (PSG) devices market is experiencing strong growth driven by the rising prevalence of sleep disorders, coupled with greater awareness about sleep health that is encouraging more people to seek diagnosis. The growing demand for home sleep testing is expanding access to convenient and cost-effective diagnostics, while technological advancements such as wireless sensors and AI-driven analysis are improving accuracy and patient comfort. Additionally, active product development by key market players is bringing innovative solutions to market, collectively boosting the adoption and expansion of PSG devices worldwide.

What are the latest Polysomnography Devices Market Dynamics and Trends?

The market for polysomnography devices is gaining pace at present owing to the increasing prevalence of sleep disorders such as obstructive sleep apnea, insomnia, and narcolepsy.

According to recent analysis by DelveInsight (2024), the diagnosed prevalence of insomnia has risen gradually, driven by stress, demanding lifestyles, and increased awareness, alongside advancements in sleep medicine and personalized therapies. In 2023, the estimated number of diagnosed cases across the 7MM was approximately 87,051.

Additionally, as per our analyst estimation (2024), approximately, 937 million adults around the world were estimated to have mild to severe obstructive sleep apnea.

Insomnia, often linked to stress and modern lifestyles, requires precise monitoring to tailor personalized therapies, while OSA, being underdiagnosed yet strongly associated with cardiovascular and metabolic risks, necessitates reliable detection through PSG testing. These staggering prevalence numbers highlight the urgent need for both in-lab PSG systems for complex cases and portable PSG devices for mass screening and home-based diagnosis, ultimately driving significant growth in the PSG devices market as healthcare providers strive to manage the rising patient population effectively.

Furthermore, the increasing demand for home sleep testing is significantly escalating the market for polysomnography (PSG) devices, as patients increasingly prefer convenient and cost-effective diagnostic solutions over traditional in-lab studies.

Home-based PSG devices enable accurate detection of sleep apnea and other disorders in a comfortable environment, improving patient compliance and accessibility to care. For instance, in September 2024, the SANSA patch received FDA 510(k) clearance as a home sleep apnea test, capturing signals like SpO2, ECG-derived heart rate, respiratory effort, actigraphy, and more, with AI-powered analysis. Thus, these approvals and launches exemplify the ongoing shift toward home-based sleep diagnostics.

However, the high competition from alternative technologies such as wearables, consumer sleep trackers, and simplified home sleep apnea tests (HSAT) and stringent regulatory process for product approval may hinder the future market of polysomnography devices.

Polysomnography Devices Market Segment Analysis

Polysomnography Devices Market by Product Type (Stationary and Portable), Channel Configuration (>10 Channels, >16 Channels, >32 Channels, and >36 Channels), End-User (Hospitals, Clinics, and Homecare Settings), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

By Product Type: Stationary Category Dominates the Market

Within the product type segment of the polysomnography devices market, stationary PSG devices are anticipated to dominate, accounting for around 60% of the share in 2024. Stationary polysomnography (PSG) devices are significantly boosting the overall PSG devices market, as they remain the gold standard for comprehensive sleep disorder diagnostics in clinical and hospital environments. These systems are highly valued for their ability to provide in-depth, multi-channel monitoring of parameters such as brain activity, respiratory effort, cardiac function, oxygen saturation, and muscle movements, which are crucial for diagnosing complex sleep disorders like obstructive sleep apnea (OSA), narcolepsy, and parasomnias. For example, Natus Medical's Nicolet(R) EEG/PSG system is widely adopted in sleep laboratories and hospitals because it offers high-resolution data capture, seamless integration with hospital IT systems, and advanced analysis capabilities, making it a preferred choice for cases requiring detailed evaluation.

Despite the rising demand for portable and home-based PSG devices, stationary PSG systems are indispensable for patients with comorbidities or severe sleep-related conditions where real-time monitoring under clinical supervision is critical. Hospitals and specialized sleep clinics continue to invest in these devices due to their ability to accommodate multiple patients, support AI-driven automated scoring, and provide reliable long-term data storage for research and clinical follow-ups. Additionally, advancements such as wireless sensor connectivity, cloud-enabled data sharing, and compatibility with telehealth platforms are further enhancing their value. Consequently, stationary PSG devices not only sustain a major revenue stream but also set the benchmark for diagnostic accuracy and innovation, thereby fueling the overall growth of the PSG devices market.

Thus, the factors mentioned above are expected to boost the category thereby, boosting the overall market of polysomnography devices across the globe.

By Channel Configuration: >36 Channels Dominates the Market

In the polysomnography devices market, the >36 channels category is projected to hold the largest share of approximately 48% within the channel configuration segment in 2024. The availability of >36 channel polysomnography (PSG) devices is boosting the overall market by enabling more comprehensive and accurate sleep studies. These high-channel systems allow clinicians to monitor a wider range of physiological parameters simultaneously such as brain activity, eye movement, muscle tone, airflow, respiratory effort, and cardiac signals leading to better diagnosis of complex sleep disorders like sleep apnea, narcolepsy, and parasomnias. For example, the Compumedics Grael(R) HD-PSG/EEG system offers >36 channels with high-definition recording, giving sleep labs advanced diagnostic capability and improving clinical confidence. The ability to provide such detailed data supports precision medicine, encourages adoption in specialized sleep centers, and fuels the growth of the PSG devices market.

By End-User: Hospitals Dominates the Market

In the polysomnography devices market, Hospitals are expected to account for the largest end-user segment in 2024, due to their strong infrastructure, availability of specialized sleep laboratories, and access to skilled healthcare professionals. These settings can conduct comprehensive sleep studies with advanced PSG systems, ensuring accurate diagnosis and effective treatment planning for a wide range of sleep disorders. Moreover, the rising prevalence of conditions like obstructive sleep apnea and insomnia, coupled with increased patient preference for hospital-based sleep studies, further drives adoption. As a result, Hospitals remain the primary hubs for PSG testing, solidifying their dominance in the market.

Polysomnography Devices Market Regional Analysis

North America Polysomnography Devices Market Trends

North America is projected to dominate the global polysomnography devices market in 2024, accounting for approximately 45% of the total share, driven by the high prevalence of sleep disorders, particularly obstructive sleep apnea, a large undiagnosed population, advanced healthcare infrastructure, and favorable reimbursement policies. The region also benefits from strong adoption of innovative technologies and the presence of leading players like Philips Respironics, Natus Medical, and ResMed.

Insomnia is a significant health issue in the United States, and its prevalence has been increasing over the past few decades. According to DelveInsight estimates, among the 7MM, the US has the highest number of cases of Insomnia accounting for 67% of cases alone in 2023. Additionally, as per our analyst estimates (2025), approximately 60.5 million Americans suffered from poor sleep quality, and more than 40.2 million meet the diagnostic criteria for sleep disorders. PSG devices play a critical role in identifying and monitoring sleep abnormalities, enabling effective treatment planning. This growing patient pool directly translates into higher adoption of PSG devices across hospitals, clinics, and sleep centers, thereby significantly fueling market growth.

Furthermore, awareness initiatives, such as the National Sleep Foundation's Sleep Awareness Week(R) 2024, are further promoting early diagnosis by educating people on the risks of untreated sleep disorders. Such initiatives are driving patients to hospitals, clinics, and sleep labs, increasing the utilization of PSG devices for comprehensive sleep studies and, in turn, fueling market growth.

On the product development front, several impactful approvals and product launch have signaled robust advancements which further boost the market of PSG devices across the region. For instance, in August 2025, Nox Medical, a global leader in sleep care management solutions, diagnostic technologies, and prescription digital therapeutics, announced the U.S. launch of the Nox SAS(TM) solution, an advanced EEG technology that simplified clinically rigorous PSG testing across various settings.

Therefore, the factors mentioned above are expected to drive the growth of the polysomnography devices market in North America.

Europe Polysomnography Devices Market Trends

Europe is playing a significant role in driving the growth of polysomnography devices market, the region has a high prevalence of sleep disorders. As per the recent estimates of DelveInsight (2024), approximately 10.5% of European population was suffering from insomnia. Thus, this growing burden of sleep disorders has increased the demand for advanced PSG devices in both hospital and home-care settings, encouraging healthcare providers and policymakers in the region to invest in sleep diagnostics. Moreover, increasing awareness campaigns by organizations like the European Sleep Research Society (ESRS) and the launch of innovative PSG solutions by regional players are further fueling market expansion across Europe.

Asia-Pacific Polysomnography Devices Market Trends

Asia-Pacific is emerging as a major growth driver for the polysomnography devices market due to its rapidly rising patient pool for sleep disorders including obstructive sleep apnea, insomnia, driven by aging populations. DelveInsight estimates indicate that in 2023, the obstructive sleep apnea gender-specific diagnosed prevalence in Japan was approximately 3,193 thousand cases for males and 1,820 thousand cases for females. Additionally, the growing awareness about early diagnosis of sleep disorders is fueling the adoption of advanced polysomnography devices across the region.

Who are the major players in the polysomnography devices market?

The following are the leading companies in the polysomnography devices market. These companies collectively hold the largest market share and dictate industry trends.

• Koninklijke Philips N.V.
• Compumedics Limited
• Natus Medical Incorporated
• Nox Medical, ResMed
• SOMNOmedics GmbH
• Cadwell Industries, Inc.
• CleveMed
• Nihon Kohden Corporation
• Grass Technologies
• Medcare
• Vyaire Medical
• Neurovirtual
• Cidelec
• BMC Medical
• Natus Medical Incorporated
• Bitmed
• Neurosoft
• Recorders & Medicare Systems
• EB Neuro
• Others

How is the competitive landscape shaping the polysomnography devices market?

The competitive landscape of the polysomnography (PSG) devices market is shaping up with a mix of established global players and emerging regional companies, making it moderately consolidated. Leading players such as Philips Healthcare, Natus Medical, Compumedics, and Nox Medical dominate the market with strong product portfolios, advanced sleep diagnostic technologies, and wide distribution networks. These companies are increasingly focusing on innovation, FDA and CE approvals, and partnerships with sleep labs and hospitals to strengthen their positions. At the same time, new entrants and regional players are introducing cost-effective portable PSG devices to capture emerging markets, particularly in Asia-Pacific and Latin America. While the market is somewhat consolidated among top-tier players, increasing demand for home sleep testing solutions is encouraging competition and diversification, gradually reducing concentration and creating opportunities for smaller firms to expand their footprint.

Recent Developmental Activities in the Polysomnography Devices Market

• In August 2025, Nox Medical, a global leader in sleep care management solutions, diagnostic technologies, and prescription digital therapeutics, announced the U.S. launch of the Nox SAS(TM) solution, an advanced EEG technology that simplified clinically rigorous PSG testing across various settings.
• In June 2025, DormoTech unveiled its latest wireless, AI-powered home sleep diagnostics platform, the DormoVision X, during the SLEEP 2025 conference in Seattle. This system received FDA clearance in December 2024, under the name DormoTech Nlab.
• In September 2024, Cerebra Medical Ltd. secured FDA market clearance for its Cerebra Sleep System, a lab-quality in-home PSG system that patients can self-apply without a technician.
• In March 2024, Beacon Biosignals received FDA 510(k) clearance for SleepStageML, a breakthrough AI-powered sleep staging software designed to work with clinical PSG recordings.
• In February 2024, EnsoSleep PPG (EnsoData), announced that the FDA granted 510(k) clearance to EnsoData's EnsoSleep PPG an AI-driven diagnostic tool that analyzes photoplethysmogram (PPG) signals (e.g., from wearable pulse oximeters) to detect sleep-disordered breathing and sleep stages.

Polysomnography Devices Market Segmentation

• Polysomnography Devices Product Type Exposure
• Portable
• Stationary
• Polysomnography Devices Channel Configuration Exposure
• >10 Channels
• >16 Channels
• >32 Channels
• >36 Channels
• Polysomnography Devices End-Users Exposure
• Hospitals
• Clinics
• Homecare Settings
• Polysomnography Devices Geography Exposure
• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Spain
• Rest of Europe
• Asia-Pacific
• China
• Japan
• India
• Australia
• South Korea
• Rest of Asia-Pacific
• Rest of the World
• South America
• Middle East
• Africa

Impact Analysis

AI-Powered Innovations and Applications:

AI-powered innovations in PSG devices are revolutionizing sleep diagnostics by automating data analysis, improving accuracy, and enabling real-time insights. Traditionally, PSG studies required manual scoring of multiple parameters such as EEG, ECG, airflow, oxygen saturation, and muscle activity, which was time-consuming and prone to variability. With AI integration, PSG devices now use machine learning algorithms to automatically detect sleep stages, respiratory events, and abnormal patterns with higher precision. For example, Compumedics Limited has integrated AI algorithms into its PSG platforms to enhance automated scoring accuracy, while Philips Respironics employs AI-driven software in its Alice NightOne and Alice 6 systems to streamline diagnostics and improve clinical workflows. Similarly, ResMed leverages AI in cloud-based platforms to interpret sleep study data remotely, supporting both in-lab and home-based PSG. These innovations not only reduce clinician workload but also improve early detection of conditions like sleep apnea, insomnia, and narcolepsy, ultimately boosting adoption of PSG devices in both hospitals and home settings.

U.S. Tariff Impact Analysis on Polysomnography Devices Market:

The U.S. government has expanded tariffs on medical devices, with a 10% universal baseline tariff now applied to most imports including PSG systems and components. Devices and parts imported from China may face tariffs as high as 54%, while those from the EU are subject to about a 20% tariff, significantly raising entry costs for non-domestic makers. Because many PSG devices rely on subcomponents such as semiconductors critical for data acquisition and signal processing any tariffs on these inputs further escalate manufacturing costs. Such cost increases can lead to higher purchase prices for sleep labs, hospitals, and home testing providers, potentially dampening demand or delaying procurement. In response, some PSG device manufacturers may be compelled to relocate production, diversify supply chains, or source components from USMCA-compliant regions (e.g., Mexico) to minimize tariff exposure. These shifts, while strategic, require investment and time to implement. Healthcare systems and providers already operating with tight budgets may see increased test costs and reimbursement pressures, which could slow adoption of new PSG technologies or favor refurbished options.

How This Analysis Helps Clients

• Cost Management: By understanding the tariff landscape, clients can anticipate cost increases and adjust pricing strategies accordingly, ensuring profitability.
• Supply Chain Optimization: Clients can identify alternative sourcing options and diversify their supply chains to reduce dependency on high-tariff regions, enhancing resilience.
• Regulatory Navigation: Expert guidance on navigating the evolving regulatory environment helps clients maintain compliance and avoid potential legal challenges.
• Strategic Planning: Insights into tariff impacts enable clients to make informed decisions about manufacturing locations, partnerships, and market entry strategies.

Key takeaways from the polysomnography devices market report study

• Market size analysis for the current polysomnography devices market size (2024), and market forecast for 8 years (2025 to 2032)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
• Key companies dominating the polysomnography devices market.
• Various opportunities available for the other competitors in the polysomnography devices market space.
• What are the top-performing segments in 2024? How these segments will perform in 2032?
• Which are the top-performing regions and countries in the current polysomnography devices market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for the polysomnography devices market growth in the future?

Frequently Asked Questions for the Polysomnography Devices Market

1. What is the growth rate of the polysomnography devices market?

• The polysomnography devices market is estimated to grow at a CAGR of 5.02% during the forecast period from 2025 to 2032.

2. What is the market for polysomnography devices?

• The polysomnography devices market was valued at USD 265.88 million in 2024, and is expected to reach USD 392.05 million by 2032.

3. Which region has the highest share in the polysomnography devices market?

• North America is expected to dominate the overall polysomnography devices market due to the high prevalence of sleep disorders, particularly obstructive sleep apnea, coupled with a large undiagnosed patient population. The region benefits from advanced healthcare infrastructure, strong adoption of innovative PSG technologies, and favorable reimbursement policies that support both in-lab and home-based sleep studies. Additionally, rising awareness about the health risks linked to poor sleep and strong presence of leading manufacturers such as Philips Respironics, Natus Medical, and ResMed further strengthen North America's market leadership.

4. What are the drivers for the polysomnography devices market?

• The polysomnography (PSG) devices market is experiencing strong growth driven by the rising prevalence of sleep disorders, coupled with greater awareness about sleep health that is encouraging more people to seek diagnosis. The growing demand for home sleep testing is expanding access to convenient and cost-effective diagnostics, while technological advancements such as wireless sensors and AI-driven analysis are improving accuracy and patient comfort. Additionally, active product development by key market players is bringing innovative solutions to market, collectively boosting the adoption and expansion of PSG devices worldwide.

5. Who are the key players operating in the polysomnography devices market?

• Some of the key market players operating in the polysomnography devices market include Koninklijke Philips N.V., Compumedics Limited, Natus Medical Incorporated, Nox Medical, ResMed, SOMNOmedics GmbH, Cadwell Industries, Inc., CleveMed, Nihon Kohden Corporation, Grass Technologies, Medcare, Vyaire Medical, Neurovirtual, Cidelec, BMC Medical, Natus Medical Incorporated, Bitmed, Neurosoft, Recorders & Medicare Systems, EB Neuro, and others.